Patients with resectable pancreatic cancer were randomized to receive either adjuvant gemcitabine or perioperative FOLFIRINOX. Perioperative FOLFIRINOX led to almost doubled median progression-free survival compared to adjuvant gemcitabine in patients who underwent surgical resection. Despite premature trial termination due to poor accrual, perioperative FOLFIRINOX showed feasibility and potential effectiveness in selected patient cohorts. Safety issues were not observed in the FOLFIRINOX arm, suggesting it as a promising treatment option for resectable pancreatic cancer.
Journal Article by Goetze TO, Reichart A (…) Al-Batran SE et 17 al. in Ann Surg Oncol
© 2024. The Author(s).